Amro Elshoury

Hematology | Oncology

8326 Naab Rd
Indianapolis, IN 46260

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms.

ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms.

Journal: Leukemia

Published: July 27, 2023

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 08, 2022

Short-Term Storage of Mobilized Peripheral Blood Stem Cells in a Closed System Changes the Microenvironment and May Affect the Quantity of CD34+ and CD34+CD38-CD45RA-CD90+ Cells.

Short-Term Storage of Mobilized Peripheral Blood Stem Cells in a Closed System Changes the Microenvironment and May Affect the Quantity of CD34+ and CD34+CD38-CD45RA-CD90+ Cells.

Journal: Transplantation and cellular therapy

Published: July 09, 2022

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 07, 2022

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 19, 2021

The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.

The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 01, 2021

Update on Guidelines for the Prevention of Cancer-Associated Thrombosis.

Update on Guidelines for the Prevention of Cancer-Associated Thrombosis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 29, 2021

How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis.

How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 18, 2021

Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.

Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.

Journal: Leukemia & lymphoma

Published: February 17, 2021

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 04, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026